MetaCap

Werewolf Therapeutics (HOWL) vs Rafael (RFL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Werewolf Therapeutics (HOWL) has outperformed Rafael (RFL) over the past year, gaining 8.4% versus a loss of 25.8%. Over five years, RFL leads with a -84.2% price change compared with -93.7% for HOWL. Rafael is the larger company by market cap ($48.0 million vs $46.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HOWL+8.43%RFL-25.83%
+218%+70%-78%
Nov 21, 20251 yearNov 20, 2026
HOWL-94.08%RFL-84.64%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HOWL versus RFL key metrics
MetricHOWLRFL
Share price$0.9466$0.9197
Market cap$46.00M$47.99M
1-day change-3.97%+2.19%
YTD return+49.31%-22.06%
1-year return+8.43%-25.83%
5-year return-93.68%-84.19%
EPS (TTM)$-0.58$-0.58
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$874.00K
Revenue growth (YoY)—-4.69%
Net income (latest FY)$-60.82M$-29.64M
Operating margin—-3822.54%
Net margin—-3390.73%
52-week high$1.20$3.96
52-week low$0.27$0.781
Distance from 52-week high-21.12%-76.78%
Analyst consensusnone—
Avg. price target upside+639.49%—
Average volume1.08M140.84K
Shares outstanding48.60M51.39M
Employees3921
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HOWL has outperformed RFL by 34.3 percentage points over the past year.

About Werewolf Therapeutics

HOWL stock →

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

About Rafael

RFL stock →

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

HOWL vs RFL FAQ

Which is bigger, Werewolf Therapeutics or Rafael?

Rafael (RFL) is larger, with a market capitalization of $47.99M compared with $46.00M for Werewolf Therapeutics (HOWL).

Which stock has performed better over the past year, HOWL or RFL?

HOWL returned +8.43% over the past 12 months, compared with -25.83% for RFL (price return, excluding dividends). Past performance does not predict future results.

Are Werewolf Therapeutics and Rafael in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons